Betamethasone is a potent, long-acting synthetic glucocorticoid with high anti-inflammatory, immunosuppressive, and anti-allergic activity. The 4mg/ml concentration is typically available as an injectable solution for intramuscular, intravenous, intra-articular, intralesional, or soft tissue administration. It is approximately 8-10 times more potent than prednisolone. In the Indian context, it is widely used for rapid control of severe inflammatory and allergic conditions, including acute exacerbations of chronic diseases.
Adult: Dose varies widely by indication and route. **Systemic (IM/IV):** Initial: 0.5-9 mg/day (0.125-2.25 ml of 4mg/ml solution). Severe conditions: 4-8 mg (1-2 ml) IM/IV initially, repeated as needed. **Intra-articular/Soft Tissue:** Large joints (knee, ankle): 1-2 ml (4-8 mg). Medium joints (elbow, wrist): 0.5-1 ml (2-4 mg). Small joints/bursae: 0.25-0.5 ml (1-2 mg). **Intralesional:** 0.2 ml/cm² (up to 1 ml per site).
Note: **For IM injection:** Use deep gluteal muscle. Avoid deltoid for volumes >1 ml. **For IV injection:** Administer undiluted or diluted in compatible IV fluid (e.g., NS, D5W) over several minutes. **For intra-articular:** Strict aseptic technique. Confirm needle is in joint space (aspirate synovial fluid if possible). Do not inject into unstable/infected joints. Rest joint for 24-48 hours post-injection. Do not use for more than 3-4 injections per year per joint.
Betamethasone binds to specific intracellular glucocorticoid receptors, forming a complex that translocates to the cell nucleus. This complex modulates gene transcription by binding to glucocorticoid response elements (GREs) or interacting with transcription factors like NF-κB and AP-1. The net effect is the suppression of synthesis of pro-inflammatory proteins (cytokines, enzymes, adhesion molecules) and promotion of anti-inflammatory proteins.
Pregnancy: FDA Category C. May cause fetal harm. Crosses placenta. Use only if potential benefit justifies risk. Chronic use associated with low birth weight, adrenal suppression in neonate. Antenatal use for fetal lung maturation is a specific indication (betamethasone is drug of choice).
Driving: May cause dizziness, vertigo, or visual disturbances. Patients should not drive or operate machinery if affected.
| Warfarin/Anticoagulants | Betamethasone may alter response; monitor INR closely. | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Increased risk of GI ulceration and bleeding. | Major |
| Diuretics (e.g., Furosemide, Hydrochlorothiazide) | Enhanced potassium loss, risk of severe hypokalemia. | Major |
| Antidiabetics (Insulin, Metformin) | Betamethasone causes hyperglycemia; may require dose adjustment of antidiabetics. | Major |
| Live Vaccines (MMR, Varicella, OPV) | Increased risk of vaccine-induced infection; avoid. | Contraindicated |
| Enzyme Inducers (Phenobarbital, Phenytoin, Rifampicin) | Increased metabolism of betamethasone, reducing its efficacy. | Moderate |
| Enzyme Inhibitors (Ketoconazole, Itraconazole) | Decreased metabolism of betamethasone, increasing toxicity risk. | Moderate |
| Cardiac Glycosides (Digoxin) | Hypokalemia potentiates digitalis toxicity. | Major |
| Amphotericin B | Potentiates hypokalemia. | Major |